We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Read MoreHide Full Article
Stereotaxis (STXS - Free Report) and Shanghai MicroPort EP recently announced the regulatory approval of the Genesis Robotic Magnetic Navigation (RMN) System by China’s National Medical Products Administration (NMPA). With this approval, MicroPort EP is likely to initiate a full commercial launch of Genesis through its existing sales teams focused on the electrophysiology community.
NMPA’s approval of the Genesis RMN System is a key element in a broader collaboration between Stereotaxis and MicroPort EP, which is likely to entail the development, integration and commercialization of Stereotaxis’ robotic system, robotically navigated catheters and MicroPort EP’s Columbus 3D mapping system.
Likely Trend of STXS Stock Following the News
Following the announcement, shares of the company moved nearly 10.2% north to $2.26 at yesterday’s closing. In the past year, STXS shares have gained 33.7% compared with the industry’s 15.1% growth. The S&P 500 increased 31.6% in the same time frame.
Meanwhile, STXS currently has a market capitalization of $173.7 million.
Image Source: Zacks Investment Research
More on STXS’ Genenis RMN System
The Genesis RMN System is designed as a powerful Robotic Magnetic Navigation System with unprecedented responsiveness to physician control. The system combines the benefits of Robotic Magnetic Navigation and the speed and responsiveness of Genesis in a form factor that can be easily, rapidly and broadly adopted. The system is semi-mobile and can be set up in a cath lab over a weekend.
The Genesis magnets are held on flexible robotic arms that offer increased system angulation and associated imaging angulation. Advanced electronics and modern technology incorporated across all aspects of the system support improved performance, reliability and size compared to previous RMN systems. The entire system is significantly smaller and designed to improve the patient experience while on the operating table provide physicians and nurses with greater access to the patient during the procedure and increase space in the labs for an enhanced work environment.
The NMPA clearance of the Genesis RMN System is a significant milestone, making available the latest advances in minimally invasive robotic technology to physicians and patients in China. It is likely to bolster the collaboration between Stereotaxis and MicroPort EP and help STXS commercializing its robotic system in China.
The Genesis RMN System is CE-marked and FDA-cleared, and hundreds of patients have been treated with these systems in the United States and Europe. In November, STXS announced that physicians at the University of Kansas Health System successfully treated the first patients using the advanced Genesis RMN System.
STXS’ Other Notable Developments
In August, STXS received a CE mark in Europe for GenesisX — a next-generation robotic system. The company also submitted a 510(k) application to the FDA in the United States for the same.
In May 2024, Stereotaxis successfully treated its first heart rhythm patients from Penn Presbyterian Medical Center using the advanced Genesis Robotic Magnetic Navigation System.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
Stereotaxis (STXS - Free Report) and Shanghai MicroPort EP recently announced the regulatory approval of the Genesis Robotic Magnetic Navigation (RMN) System by China’s National Medical Products Administration (NMPA). With this approval, MicroPort EP is likely to initiate a full commercial launch of Genesis through its existing sales teams focused on the electrophysiology community.
NMPA’s approval of the Genesis RMN System is a key element in a broader collaboration between Stereotaxis and MicroPort EP, which is likely to entail the development, integration and commercialization of Stereotaxis’ robotic system, robotically navigated catheters and MicroPort EP’s Columbus 3D mapping system.
Likely Trend of STXS Stock Following the News
Following the announcement, shares of the company moved nearly 10.2% north to $2.26 at yesterday’s closing. In the past year, STXS shares have gained 33.7% compared with the industry’s 15.1% growth. The S&P 500 increased 31.6% in the same time frame.
Meanwhile, STXS currently has a market capitalization of $173.7 million.
Image Source: Zacks Investment Research
More on STXS’ Genenis RMN System
The Genesis RMN System is designed as a powerful Robotic Magnetic Navigation System with unprecedented responsiveness to physician control. The system combines the benefits of Robotic Magnetic Navigation and the speed and responsiveness of Genesis in a form factor that can be easily, rapidly and broadly adopted. The system is semi-mobile and can be set up in a cath lab over a weekend.
The Genesis magnets are held on flexible robotic arms that offer increased system angulation and associated imaging angulation. Advanced electronics and modern technology incorporated across all aspects of the system support improved performance, reliability and size compared to previous RMN systems. The entire system is significantly smaller and designed to improve the patient experience while on the operating table provide physicians and nurses with greater access to the patient during the procedure and increase space in the labs for an enhanced work environment.
The NMPA clearance of the Genesis RMN System is a significant milestone, making available the latest advances in minimally invasive robotic technology to physicians and patients in China. It is likely to bolster the collaboration between Stereotaxis and MicroPort EP and help STXS commercializing its robotic system in China.
The Genesis RMN System is CE-marked and FDA-cleared, and hundreds of patients have been treated with these systems in the United States and Europe. In November, STXS announced that physicians at the University of Kansas Health System successfully treated the first patients using the advanced Genesis RMN System.
STXS’ Other Notable Developments
In August, STXS received a CE mark in Europe for GenesisX — a next-generation robotic system. The company also submitted a 510(k) application to the FDA in the United States for the same.
In May 2024, Stereotaxis successfully treated its first heart rhythm patients from Penn Presbyterian Medical Center using the advanced Genesis Robotic Magnetic Navigation System.
STXS’ Zacks Rank & Stocks to Consider
STXS carries a Zacks Rank #3 (Hold) at present.
Some better-ranked stocks from the medical industry are Masimo (MASI - Free Report) , AngioDynamics (ANGO - Free Report) and Globus Medical (GMED - Free Report) .
Masimo, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 10.4% for 2025. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 17.10%. Masimo’s shares have risen 37.2% year to date compared with the industry’s 6.7% growth.
AngioDynamics, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 38.2% for 2025. ANGO’s earnings surpassed estimates in three of the trailing four quarters and missed once, delivering an average surprise of 31.71%.
AngioDynamics’ shares have lost 8.9% year to date against the industry’s 6.7% growth.
Globus Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.7%. GMED’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 12.1%. Its shares have risen 56.5% year to date compared with the industry’s 6.7% growth.